Price
No data yet.
Social Signal Score
Analyst Ratings
38 analystsRevenue
$50.47B+135.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gail Koziara Boudreaux
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Employees
- 96,615
- Beta
- 0.70
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.12
Financials
Revenue
$50.47B+135.7%Net Income
$1.46B+136.8%EBITDA
$2.10B+52.1%Free Cash Flow
$1.63B+103.5%EPS (diluted)
$6.71+191.7%Shares Outstanding (diluted)
217.90M-18.7%Operating Expenses
$0.00Cash & Debt
$37.51BReturn of Capital
$607.00MRevenue by Segment (annual)
$197.12BDividend per Share
$1.72Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $199.13B | $5.66B | $25.18 |
| 2024 | $176.81B | $5.98B | $25.81 |
| 2023 | $171.34B | $5.99B | $25.38 |
| 2022 | $156.59B | $5.89B | $24.56 |
| 2021 | $138.64B | $6.10B | $25.25 |
| 2020 | $121.87B | $4.57B | $18.23 |
| 2019 | $104.21B | $4.81B | $18.81 |
| 2018 | $92.11B | $3.75B | $14.53 |
| 2017 | $90.04B | $3.84B | $14.70 |
| 2016 | $84.98B | $2.47B | $9.39 |
| 2015 | $79.24B | $2.56B | $9.73 |
| 2014 | $73.92B | $2.57B | $9.31 |
| 2013 | $71.12B | $2.65B | $8.89 |
| 2012 | $61.53B | $2.66B | $8.26 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ELV's reported EPS growth of 9.0% a year over 13 years.
- EPS in 5 years
- $39.28
- Implied price
- $549.88
- Return from $386.43
- 7.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $273.39 — -29.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -1.0% | -8.9% | -5.5% | -2.5% | 0.1% | 2.5% |
| 4.0% | -4.3% | -0.7% | 2.4% | 5.2% | 7.7% |
| 9.0% | 0.3% | 4.1% | 7.3% | 10.2% | 12.8% |
| 14.0% | 4.9% | 8.8% | 12.2% | 15.3% | 18.0% |
| 19.0% | 9.5% | 13.6% | 17.2% | 20.3% | 23.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
34-31.11%Social Signal Score
Mentions (10)
- News (RSS)zerohedge·13d ago·Negative
White House Cancels Coverage For 750,000 ACA Enrollees, Citing Fraud White House Cancels Coverage For 750,000 ACA Enrollees, Citing Fraud Vice President JD Vance said Tuesday that about 750,000 people on Affordable Care Act plans were never entitled to the coverage, and that pulling their subsidies will save taxpayers $2.2 billion. Mehmet Oz, who runs the Centers for Medicare and Medicaid Services, stood with him. The savings number is an administration estimate. The Congressional Budget Office
View source ↗ - News (RSS)seekingalpha·22d ago·Neutral
Elevance leads UBS health benefits survey as employers brace for higher costs
View source ↗ - News (RSS)forbes·22d ago·Neutral
Is The Health Insurer Rebound Complete? Some Seem To Think So An increasing number of industry analysts say costs are under control for the likes of CVS Health, Centene, Cigna, Elevance Health, Humana, UnitedHealth Group and others.
View source ↗ - Newsbenzinga.com·25d ago·Neutral
Elevance Health Stock is Moving Higher After FY26 EPS Reaffirmation Elevance Health Inc. (NYSE:ELV) shares are jumping Thursday after the company reaffirmed its full-year 2026 earnings guidance ahead of a series of investor meetings. Here's what you should know.
View source ↗ - News (RSS)financialpost·27d ago·Neutral
Elevra Lithium Announces NAL Expansion Pre-Feasibility Study BRISBANE, Australia, Sept. 08, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce the results of a Pre-Feasibility Study (“PFS”) for the staged North American Lithium (“NAL”) Brownfield Expansion in Québec. The PFS confirms the NAL Expansion as a high-value growth project that is […]
View source ↗ - News (RSS)businessinsider·27d ago·Neutral
Elevra Lithium Announces NAL Expansion Pre-Feasibility Study <link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="justify">BRISBANE, Australia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- North American lithium producer Elevra Lithium Limited (“Elevra" or "Company”) (ASX:ELV; NASDAQ:ELVR) is pleased to announce the results of a Pre-Feasibility Study ("PFS")...
View source ↗ - News (RSS)yahoo·34d ago·Neutral
Elevance Health (ELV) Soars as Investors Gain Confidence in Profitability
View source ↗ - News (RSS)yahoo·34d ago·Neutral
Elevance Health (ELV): Bridging the Gap between Care and Coverage
View source ↗ - News (RSS)yahoo·41d ago·Neutral
Is Elevance Health (ELV) a Mispriced Opportunity?
View source ↗ - Newszacks.com·52d ago·Neutral
Elevance Health (ELV) Up 6.8% Since Last Earnings Report: Can It Continue? Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
View source ↗
Earnings
Wed, Oct 21(in 2 weeks)
Consensus estimate $4.66 per share
Typical surprise +7.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 15$7.45 vs $6.21beat
- Wed, Apr 22$12.58 vs $10.82beat
- Wed, Jan 28$3.33 vs $3.10beat
- Tue, Oct 21$6.03 vs $4.93beat
- Thu, Jul 17$8.84 vs $8.91miss
- Tue, Apr 22$11.97 vs $11.41beat
Estimates and results for ELV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELV officers and directors.
- Bought
- $5.1m
- Sold
- $3.9m
8 trades
7 trades
- Peru Ramiro Gbought
- Boudreaux Gailbought
- Boudreaux Gailbought
- Penczek Ronald Wsold
- Dixon Robert L Jrsold
- Penczek Ronald Wsold
- Schulman Amy Wsold
- Kendrick Charles Morgan Jrsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Markwayne Mullinsenate · OK · disclosed Jan 16, 2026 (18d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 26, 2025 (550d later)Sell$100,001 - $250,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (33d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (242d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Sep 12, 2025 (38d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (34d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (10d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 2, 2025 (18d later)Sell$15,001 - $50,000
- Daniel Milton Newhousehouse · WA04 · disclosed May 16, 2025 (35d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed May 7, 2025 (8d later)Buy$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Apr 9, 2025 (30d later)Sell$1,001 - $15,000
- Jared Moskowitzhouse · FL23 · disclosed Apr 9, 2025 (30d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Mar 9, 2025 (13d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.